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abstract
Fetal growth restriction (FGR) is the failure of a fetus to reach its full genetic growth potential. It occurs in
up to 8% of pregnancies, and after premature birth is the second leading cause of infant mortality and
morbidity. There is no treatment currently available for FGR. Its primary cause, when not attributable to
structural or genetic defects of the fetus, is ‘placental insufﬁciency’. This broad deﬁnition covers the
inability of the fetus to acquire sufﬁcient nutrients and oxygen, and is inﬂuenced by a number of factors
including altered maternal or fetal blood ﬂow, reduced nutrient transport or changes in the placenta such
as increased barrier thickness inhibiting nutrient transfer. For those researchers studying FGR and
developing new therapies, choosing an animal model is a crucial consideration. It is vital to clearly frame
the question being asked, as this will impact the factor inﬂuencing fetal nutrient delivery in the model,
and will also affect the applicability of the results to the human condition. This review examines the
range of in vivo models of FGR available for those engaged in translational research.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Fetal growth restriction (FGR) is a failure of a fetus to reach its
full genetic growth potential. It occurs in up to 8% of pregnancies,
and is the second leading cause of infant mortality and morbidity,
following premature birth. Not only are the personal conse-
quences severe, care of these children places a huge ﬁnancial
burden on health care systems, and on social welfare if they
survive past infancy. Perhaps more alarmingly, there is no treat-
ment currently available for FGR. When severe and early onset,
parents may face the stark choice of delivering a very preterm and
possibly non-viable baby, or letting the fetus die in utero.
Tables 1e6.
The primary cause of FGR, when not attributable to structural
or genetic defects of the fetus, is ‘placental insufﬁciency’.T h i si sa
global term covering the failure of the fetus to acquire nutrients
and oxygen adequate for its needs, and is inﬂuenced by a number
of factors including altered maternal or fetal blood ﬂow, reduced
nutrient transport or changes in the placenta such as increased
barrier thickness inhibiting nutrient transfer. Asymmetrical FGR
can result in severe cases, a compensatory process whereby brain
growth is preserved at the expense of other structures such as
the liver, abdomen and long bones, a process termed ‘brain
sparing’.
When choosing an animal model in which to study FGR and to
develop new therapies, it is important to clearly frame the question
being asked, as this will have consequences for the factor inﬂu-
encing fetal nutrient delivery in the model, and also for the appli-
cability of the results to the human condition.
2. Why use animal models
We use animal models as the complexity they provide better
reproduces the human condition. Some aspects of pregnancy,
such as trophoblast development, placentation and placental
transport, can be studied in vitro. Human placental villous ex-
plants are used to study the maternoefetal interface. The effect
of drugs on villous growth and syncytiotrophoblast regeneration
can be investigated, or explants from patients with known pa-
thologies can be compared with normal controls for functional
studies (reviewed in Ref. [1]). Primary trophoblastic cells isolated
from placentas can be cultured short term to study cell function
and extrapolate placental remodelling [2,3]. Intricate experi-
mental techniques such as the dual perfusion model of the hu-
man placenta [4], where a complete, delivered, human placenta
is reperfused in vitro, can be used to look at utero-placental
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before the integrity of the placental barrier is compromised.
Currently, this ex vivo technique is the only model available to
study organised human placental tissue. Setting up the perfusion
experiments is complicated by a high rate of failures due to tissue
damage compromising the integrity of the placental barrier. The
technique has been used to study placental toxicology and the
transfer of drugs and endogenous (eg amino acids and hor-
mones) and exogenous (eg viruses and therapeutics) substrates
[5,6]. Dual placental perfusion has also been used in pre-
eclampsia to examine the vasodilatory effects of VEGF [7],a
Table 1
Mouse.
Advantages Disadvantages
  Small size and social nature thus
easy to maintain and relatively
inexpensive to house
  Short gestation reduces the time
and expense especially to second
and third generation studies
  Small size means may be problematic
to manipulate surgically
  Imaging of the fetus or placenta
can be technically challenging
  Can be difﬁcult to follow serially
postnatally, due to cannibalization
and the challenge of marking
newborn mice
  Differences between human
and mouse physiology, though
generally well characterized
and understood
  Altricial young
Intervention Characteristics Reference
Erk3
 /  Fetal growth restriction with 25e40%
reduction of visceral organ growth
40% die at birth from acute respiratory
failure, similar to respiratory distress
syndrome in humans
[77]
VEGF knockout Homozygous is embryonic lethal
heterozygous results in fetal growth
restriction
[65]
eNOS
 /  Fetal growth restriction with brain
sparing, hypoxia and reduced placental
system A transport
[67]
Placental speciﬁc
IGF2
 /  (P0)
30% fetal growth restriction
with brain sparing
[66]
Protein restriction Fetal growth restriction with adiposity [58]
‘Crowded uterine
horn’
Unilateral ovariectomy pre-pregnancy
producing a normal size litter
in single horn
Differential blood ﬂow results in fetal
growth restriction in the middle fetuses
[11]
Table 4
Other small mammals.
Rabbit advantages Dog advantages
  Predictable
reproductive cycle
  Familiar to regulators for
reproductive toxicology
  Fetal growth chronologically
comparable to human
  More invasive trophoblast
than other domestic animals
Intervention Characteristics Reference
Rabbit
natural model
Based on fetal position
in the uterine horn
15% fetal growth restriction
Depressed expression
of IGF-1 mRNA and lower
serum and amniotic ﬂuid
levels of IGF-1 protein
[14]
Rabbit thermal
placental injury
30% fetal growth restriction
with brain sparing
[88]
Rabbit high
cholesterol diet
15% fetal growth restriction [89]
Rabbit selective
uterine artery ligature
28% fetal growth restriction
increased fetal mortality
compared to undernutrition
Doppler parameters more closely
reproduce human FGR
[50]
Canine acute nutrient
restriction
10% fetal growth restriction
alterations in fasting glucose
and fat metabolism
[90]
Table 3
Guinea pig.
Advantages Disadvantages
  Haemomonochorial
placenta
  Extensive trophoblast
invasion
  Longer gestation, better
for therapeutic evaluation
  Precocial young thus brain
development more like
human than other rodents
  Longer gestation, larger animal,
smaller litters thus more expensive
  Less common laboratory animal
so speciﬁc reagents/equipment
more expensive
Intervention Characteristics Reference
Uterine artery
ligation
40e60% fetal growth restriction
in a proportion of fetuses
High rate of fetal death
Reduced oxygen and nutrient
delivery to fetus
[42,86,87]
Radial artery
diathermy
30% fetal growth restriction
with brain sparing reduction
in brain growth, both volume
and neuronal number
[46]
Maternal nutrient
restriction
Both acute fasting and chronic
restriction effective 10e39% fetal
growth restriction with brain sparing
altered trophoblast density, placental
barrier thickness
[52,54]
Table 2
Rat.
Advantages Disadvantages
  Short gestation,
large litters
  Large enough for complex
surgical intervention
  Useful for intergeneration
studies especially cognitive
  More expensive due
to size increase over mice
  Altricial young
Intervention Characteristics Reference
Uterine artery
ligation
40% fetal growth restriction
with brain sparing high
level fetal loss and resorption
[44]
Uterine artery
occlusion (60 min)
Fetal growth restriction
with brain sparing
fetal mortality 14%
[78]
Dexamethasone
administration
15% fetal growth restriction
chronic hypertension
in adult offspring
[79]
L-NAME
administration
Fetal growth restriction
up to 20%, increased
stillbirth dependent on
dose regimen
[80,81]
Hypoxia Both chronic and intermittent
hypoxia in second half of
pregnancy effective
4e37% fetal growth restriction,
varied level of exposure
[82e84]
Nutrient restriction Fetal growth restriction up to
35% both acute fasting and chronic
restriction effective signiﬁcant
changes to the IGF axis in offspring
[51,55,85]
Protein restriction 15% fetal growth restriction [59]
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playing a role in altered placental angiogenesis in FGR [8,9].
Nevertheless, despite the advances made using in vitro models of
some aspects of pregnancy, the condition of FGR as a whole is
more accurately represented in vivo. Still other features of
pregnancy, such as the development of the uteroplacental cir-
culation, fetal growth velocity and fetal development have no
in vitro counterpart. When new therapies become available,
although they are ﬁrst tested extensively in vitro, they must
present a clean reproductive toxicology panel in vivo [10] before
they are deemed ﬁt for use in humans, hence animal experiments
are necessary.
3. Considerations when studying animal pregnancies
There are a number of species-speciﬁc factors to be considered
when using animals to model human pregnancy. The number of
offspring per pregnancy, placentation, gestation length, parturition
and fetal versus neonatal development will all affect the choice of
model.
3.1. Fetal number
Alarge littersizehasthe advantageofacquiringgood qualitydata
froma minimalnumberof pregnancies, reducing the overall number
of animals required. Differences between the sexes can also be
studied more easily. Additionally, animals with large litters such as
rabbitsandpigshavea‘natural’modelfor FGR intheruntof thelitter.
These animals canalsobe‘forced’ intocreatingrunts where anormal
size litter is carried in a single uterine horn following a unilateral
ovariectomy [11,12]. For rabbits, pups in the middle of the uterine
horn are consistently smaller than their littermates, as they are
further away from the blood supply arriving via ovarian or cervical
ends of the uterine artery. In a natural rabbit model of FGR, when
comparedtokitsinthe‘favoured’positionsnearerthearterialsource,
runtsareconsistentlysmaller.Atterm,theweightratiooffavouredto
FGR fetus is 0.85 [13,14]. They also have depressed liver, kidney, and
intestinal expression of insulin growth factor 1(IGF-1) mRNA as well
as lower serum and amniotic ﬂuid levels of IGF-1 protein, a key
component in modulating fetal growth that is reduced in the cord
blood at term of human babies with FGR [14]. Piglet runts sponta-
neously display asymmetric growth restriction [15]. For direct fetal
treatment however, a large numberof fetuses can make intervention
technically difﬁcult. Fetal measurements can also be challenging and
time-consuming, and interventions may have a prolonged anaes-
thetic time. There are also statistical considerations to be taken into
accountwithlitters.Pupbirthweightvarieswithposition,watershed
area, sex, number, gestational age at delivery and intervention.
Importantly, when considering interventions given to mothers, the
mother is the unit of measurement and pups are nested within
mothers. Sample size calculations and analysis of the primary and
secondaryoutcomesinastudymustaccountforallthesefactorstobe
able to see the true effect of an intervention.
3.2. Length of gestation
Small animals, such as rodents and rabbits, tend to have short
gestation lengths. Much of the development that would take place
during fetal life in the human occurs in the neonatal period in these
animals. This makes them less relevant as models for the conse-
quences of FGR in the neonate, especially with regard to neuro-
logical impact. However, their shorter lifespan is an advantage for
the study of trans-generational effects, signiﬁcantly reducing the
time needed to gather data. Among rodents the guinea pig is an
exception, having a comparatively long gestation, but there is a lack
of genetic models of disease in this species. A long gestation length
can also confer considerable advantages. There is an increased time
in which to evaluate the effect of a therapy or intervention on
multiple parameters such as fetal development, fetal growth, and
miscarriage rates. These advantages must be weighed against the
cost of maintaining animals over the longer period, ﬁnally coming
down to a justiﬁcation of the cost of the model versus the quality
and type of data that it will provide.
3.3. Placental shape
Placentation is a complex process, and as the majority of FGR
arises from placental insufﬁciency there are several aspects of
Table 5
Other large mammals.
Sheep advantages Sheep disadvantages
  Serial sampling from both sides
of the placental barrier in
unanaesthetised and unstressed
animal possible
  Sheep conceptus relevant
to human fetal physiology
  Consistent gestation with
predominantly singleton pregnancies
  Good tolerance for in utero manipulation
  Placentation is not closely
similar to human
  Large animal facility needed
Intervention Characteristics Reference
Pig natural runt Asymmetrical fetal growth restriction,
improved cerebral oxygen utilisation
[15,91]
Sheep
carunculectomy
30% fetal growth restriction reduction
in glucose consumption by placenta
and oxygen supply to the fetus,
increase in placental efﬁciency
[48,92]
Sheep nutrient
restricted adult
Mild FGR, 17% reduced uterine
blood ﬂow, reduced placental
capillary density
[50]
Sheep overfed
adolescent
FGR, brain sparing, reduced
uterine blood ﬂow (36%) and umbilical
artery blood ﬂow
[56]
Sheep
hyperthermia
46e74% fetal growth restriction with
brain sparing reduced uterine and
umbilical artery blood ﬂow
[60]
Sheep maternal
hypoxia
25% fetal growth restriction
systolic and diastolic fetal cardiac
dysfunction
[93]
Goat nutrient
or protein restriction
5e10% fetal growth restriction altered
fetal thymus, small intestine, kidney
and liver weights relative to body weight
[94]
Horse crossbreed IVF experiments in Shetland ponies
and thoroughbred racehorses, fetus is
constrained by the size of the surrogate
mother
[95]
Table 6
Non-human primates.
Advantages Disadvantages
  Genetically, closest
model to human
  Pregnancy characterised
by trophoblast invasion
of the spiral arteries
  High cost and dedicated facility needed
  Ethical considerations
  Study numbers generally small
  Interventions cause high rates of fetal loss
Intervention Characteristics Reference
Baboon nutrient
restriction
10% fetal growth restriction, changes
to fetal brain, liver, kidney, placenta
[96]
Rhesus macaque
ligation of placental
bridging vessels
6e14% fetal growth restriction
with asymmetrical growth, dependent
on time of insult, 40% reduction
in functional placenta
[97,98]
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discoidal in shape, as it is in higher primates and rodents, with a
single disc-like zone of close maternofetal contact. This provides
the highest concentration of maternofetal interdigitation, an
intricate system of folds which increases the area of contact be-
tween mother and fetus. Lower primates and pigs have a diffuse
placenta, where the interdigitation is distributed over the entire
maternofetal exchange area. Ruminants, including sheep, have a
cotyledonary placenta, in which many spot-like regions of intense
maternofetal interdigitations exist.
3.4. Interdigitation
Interdigitation can be further sub-divided into ﬁve types [16].
Folded interdigitations are the most simple, with ridge-like folds of
the chorion that ﬁt into corresponding grooves of the uterine
mucosa, and are found only in animals which have a diffuse
placenta, such as pigs. Lamellar interdigitation is more complex,
with ridges branching into parallel chorionic lamellae interspersed
with branched endometrial folds, and is seen in some types of
carnivore. The trabecular type has interdigitations fromwhich leaf-
like and ﬁnger-like villi branch, and has been described in some
monkeys. Sheep, humans and other higher primates have villous
interdigitation, where the chorion has a tree-like branching
pattern, and villi either ﬁt into endometrial crypts or are directly
bathed in maternal blood. The ﬁnal and most common type is
labyrinthine, found in rodents, where a trophoblastic mass is
permeated by a network of channels ﬁlled with maternal blood or
fetal capillaries.
3.5. Interface
The type of maternalefetal interface [16] present is important
for passive transfer of oxygen across the placenta. Across species
there appears to be a relationship between the number of cell
layers in the placental exchange barrier and permeability [17].I n
the synepitheliochorial placenta for example, such as found in ru-
minants, there are six layers of tissue between maternal and fetal
blood [18]. This compares to one syncytiotrophoblast layer in the
late gestation haemomonochorial human placenta. Perfusion ex-
periments and calculations suggest that the permeability of the
sheep placenta is at least one order of magnitude less than that of
the human [19]. In an endotheliochorial placenta, seen primarily in
carnivores, invading trophoblasts face the maternal endothelium
and only ﬁve tissue layers separate the maternal and fetal circula-
tion. In a haemochorial placenta, the trophoblasts also erode the
maternal vessels and so maternal blood bathes the syncytio-
trophoblast and there are just three tissue layers between maternal
and fetal blood. Depending on the number of trophoblastic
epithelial layers a more detailed subdivision has been proposed,
which in humans depends on the gestational age: haemotrichorial
(rat and mouse), haemodichorial (rabbit and human in the ﬁrst
trimester), and haemomonochorial (great apes, guinea pig and
human at term). This has implications for drug testing in animals.
For example, if placental transfer of a drug intended for early
pregnancy were being investigated, a rabbit model may be
preferred. If the drug was tobe administeredonlyin late pregnancy,
a guinea pig model may be more appropriate.
3.6. Placental transport
A maternalefetal counter current arrangement is deemed the
most efﬁcient anatomical arrangement of blood vessels, yet pla-
centas with counter current ﬂows, such as the guinea pig [20],r a t
and rabbit are not more efﬁcient than other types, such as
crosscurrent in the sheep, where fetus produced per gram placenta
(a measureof placental efﬁciency) is equivalent [21]. Facilitated and
active transports are important to overall placental efﬁciency, as is
the total surface are available for diffusion. Nutrients such as
glucose and lactate are transferredacross the placenta by facilitated
transport via transporter proteins. There are several isoforms of the
glucose transporter, which are differentially distributed in the hu-
man placenta, and vary from distribution in other animals
(reviewed in Ref. [22]). Active transport of essential amino acids
and ions such as sodium and potassium is mediated by a range of
speciﬁc transporters, and the activityof these transportersmayalso
differ between species [23]. Alterations in the activity of certain
nutrient transporters have been seen in human FGR [24,25] and
some animal models of FGR [23,25e27]. Transport of proteins
across the placenta is largely restricted to proteins of speciﬁc use to
the fetus, such as immunoglobins, although this is conﬁned to
hemochorial placentas. Active transport of immunoglobulins oc-
curs via the placenta in humans, and via the yolk sac in rodents and
rabbits [28]. In contrast to the human placenta, epithelio- and
endotheliochorial placentas are impermeable to proteins, and
immunoglobins are transferred in the colostrum after birth [16].
Examination of the maternal and/or fetal immune response to fetal
interventions in these animal models therefore needs to consider
this aspect when trying to translate into the clinical situation.
3.7. Trophoblast invasion
The extent to which fetal trophoblast invade the maternal tissue
and remodel the spiral arteries is also an important consideration.
No other organism has such extensive invasion as humans, and
both the extent and depth of trophoblast invasion is suboptimal in
FGR [29]. Trophoblast invasion is shallow in most rodents, with rats
having more extensive invasion than mice, where uterine artery
transformation is more dependent on maternal factors such as
natural killer cells, than on trophoblast invasion [30,31]. In humans,
trophoblast invasion is crucial to adequate supply of blood to the
placenta, so the mouse would not be a suitable model for investi-
gation into the causes of inadequate spiral artery remodelling, nor
any interventions aimed at promoting trophoblast invasion. In
contrast, the guinea pig has extensive trophoblast invasion, which
spreads deep into the walls of the uterine arteries [32,33]. The
sheep, as with other ruminants, has no trophoblast invasion, and
while the maternal vessels in the rabbit are lined with multinu-
cleated cells it has not been established that these are trophoblastic
[30]. The canine placenta is more invasive than other domestic
animal models, however it more closely resembles a human pre-
eclamptic transformation than a normal pregnancy [34]. As the
nearest genetic relative tothe human, it is unsurprising that in non-
human primates the remodelling of the spiral arteries following
trophoblast invasion most closely resembles the human condition
[35,36]. Even so, there remain some differences between the spe-
cies, such as a relative lack of interstitial trophoblast cells in non-
human primates.
4. Creating animal models of fetal growth restriction
Animal models of FGR fall into three broad categories when
divided by method of intervention creating the model: fetal inter-
vention, maternal intervention, and genetic models. For each
commonly used species we list a selection of FGR models in
Tables 1e6. The primary model using fetal intervention is the
hypoxic chick [37e39]. The principal advantage of this model is the
ability to investigate the effects of hypoxia in the fetus in isolation,
without affecting the mother. In many growth restricted human
pregnancies caused by placental insufﬁciency, there is no alteration
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include infection with certain viruses and dosing with radioactive
iodine, however these are not useful for translational medicine.
There are a range of maternal interventions capable of creating
FGR in an animal model. The oldest interventions directly alter the
uterine circulation, reducing maternal nutrient and oxygen trans-
port to the placenta. Uterine artery ligation has been shown to
cause FGR in rats, guinea pigs, and sheep [40e44]. Similarly, radial
artery diathermy in guinea pigs and uterine artery embolization in
sheep also result in FGR [45e47]. Although the result is FGR, the
lack of an intact uteroplacental circulation in these models renders
them less useful for testing maternal therapies that target uterine
blood ﬂowor the placental barrierdirectly. A related intervention is
sheep carunclectomy, in which the maternal portion of the pla-
centomes e the multiple contact points between maternal and fetal
blood circulations in the placenta e are surgically removed from
the uterus prior to pregnancy. This creates FGR in about half of
pregnancies [48], illustrating the relative redundancy of the sheep
placenta.
Global interventions in the mother are also able to cause FGR in
pregnancy. In humans, a major reduction in calorie intake is needed
to inﬂuence fetal weight, such as occurred in the World War II
Dutch famine, and the effect is dependent on the trimester of
pregnancy in which it occurs [49]. As is to be expected, maternal
nutrient restriction results in smaller fetuses with asymmetrical
growth in several models, including rat, guinea pig, rabbit, and
sheep [50e55]. Interestingly, overfeeding in an adolescent preg-
nant ewe also causes FGR, as growth of the mother is maintained at
the expense of fetal development [56]. Alternatively, restriction of
speciﬁc nutrients such as in low protein or low sodium diets, rather
than overall calorie reduction, can also impact the growth of the
fetus in several models [57e59]. Environmental factors are also
capable of inﬂuencing pregnancy outcome. Following observations
of low birthweight lambs from sheep raised in hot conditions, a
heat stress model of FGR was developed [60]. Fetuses showed ev-
idence of brain sparing, and umbilical and uterine blood ﬂow was
reduced [60,61]. The hyperthermic conditions were able to be
imposed at various time points, and highlighted that the timing of
intervention used to create the FGR model can have a large impact
on the resulting disease phenotype. Finally, pregnancy at high
altitude or a period spent in a hypoxic chamber, limiting the oxygen
supply to the mother and thereby to the placenta and fetus, can
cause FGR, though this varies by species and again is dependent on
the gestational timing of the insult. Using animals that are native or
naïve to high altitude mimics the effects seen in human pregnancy,
in which compensatory mechanisms such as altered enzymatic
antioxidant activity may contribute to native protection from some
of the consequences of a reduced oxygen tension [62].
Genetic models of FGRhavegenerallybeen created inthe mouse
(recently reviewed in Ref. [63]), aided by the wealth of molecular
information available in that species and readyaccess to embryonic
stem cells. Early knockout models proved to be overly severe, and
resulted in embryonic lethal phenotypes. Global disruption of Tis-
sue Factor, also known as platelet tissue factor, factor III, throm-
bokinase, or CD142, resulted in fatal wasting of mouse offspring
after embryonic day 9.5 [64]. Unconditional knockout of vascular
endothelial growth factor(VEGF), a signal proteinwhich is essential
for angiogenesis during development, also produces an embryonic
lethal phenotype [65]. More reﬁned models are nowavailable, with
conditional or tissue-restricted knockout of speciﬁc genes. In the
placental speciﬁc insulin-like growth factor 2 (IGF2) knockout
mouse model, a transcript of the gene which is expressed only in
the placental labyrinthine trophoblast cells is deleted [66]. This
results in impaired placental growth from embryonic day 12, and
growth restriction in 96% of fetuses by embryonic day 16. Birth
weight is approximately 69% of wild type, although the pups did
exhibit postnatal catch up growth. Impaired placental growth is
seen earlier in gestation than reduced fetal growth, possibly as a
result of increased placental System A activity that may contribute
to maintaining fetal growth. Closer to term, the knockout placentas
remain smaller, the System A activity is nearer to normal and there
is decreased passive permeability as well, all of which likely
contribute to the FGR phenotype [66]. A global knockout of the
endothelial nitric oxide synthase (eNOS) gene, an enzyme which
converts arginine to nitric oxide (NO) inducing vasodilation, results
in impaired uterine artery function and diminished placental Sys-
tem A amino acid transporter activity [67]. This model shows
asymmetric growth and a possible reduction in extraction of oxy-
gen by the fetus [67]. In humans, the level of system A activity is
correlated with severity of FGR [24].
For all animal models, using a standardized method to describe
and express fetal growth is important. An examples of such a
method includes constructing fetal growth curves [68], which al-
lows comparison of animal data with human FGR data, and to
quantify how much of an improvement in fetal growth an inter-
vention might achieve in the clinic.
5. Translational medicine considerations
The practicalities of testing out drugs and therapies in animal
models of FGR present numerous challenges, both applied and
regulatory [69]. Since many models require an initial surgical
intervention, a further surgical intervention may be deemed too
stressful for the animal and may not be allowable under animal
experiment regulations governing speciﬁc countries, or may render
insufﬁcient numbers of pups for evaluation. The International
Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH) guidelines
govern reproductive toxicity studies in women and men [10],
specifying that any programme should allow exposure of the novel
chemical to all stages of development throughout one complete life
cycle: for example, from conception in one generation through to
conception in the following generation. Where more than one
investigation is used there must be an overlap between studies so
that no gaps are left between key stages. This is especially relevant
if a drug affects fertility, when there may not be adequate numbers
of pregnant animals or fetuses to properly assess developmental
toxicity in utero. In practice, a number of overlapping studies are
conducted to cover fertility and early embryonic development, pre-
and postnatal development including lactation and weaning, and
embryoefetal development [70]. All studies need to be conducted
under Good Laboratory Practice (GLP) conditions, which are
extremely costly. Fertility and pree and postnatal development
studies need only be conducted in one mammalian species, which
is commonly the rat. For embryofetal development two mamma-
lian species should usually be tested, one should be a rodent, often
the rat for pragmatic reasons, and the other a nonerodent, usually
the rabbit where there is a large body of historical data for com-
parison. Alternative species may be considered if there are good
reasons such as speciﬁcs relating to drug metabolism, although for
some species, there may not be much historical data, making
interpretation of results challenging (J Baldwin, personal
communication).
A translational medicine study is in essence a clinical trial but
performed in animals with parallel considerations. Generating the
bestcontrol groupmayrequirecollectionof local contemporaneous
data in the same species without the intervention that created FGR,
since relying on historical data may introduce bias. The type of
control group isimportant, whethertheybe untreated, have a sham
intervention or use a control treatment administration. The
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their appropriateness rather than what is permissible in a patient.
Clinical trials are run according to set principles (eg UK Clinical
Trials Regulations 2004, EU Clinical Trials Directive 2001), and an-
imal studies should follow similar principles to provide the most
robust data. Interventions should be adequately described, study
groups should be randomly allocated and blinded where possible,
sufﬁciently powered, with pre-speciﬁed clinically important end-
points and results reported together with important adverse
events. One example, the ARRIVE (Animal Research: Reporting of
In Vivo Experiments) guidelines [71], were developed as part of an
initiative by the UK National Centre for the Replacement, Reﬁne-
ment & Reduction of Animals in Research (NC3Rs). The guidelines
are intended to improve the design, analysis and reporting of
research using animals by maximising the information that is
published and minimising unnecessary studies, and have been
adopted by many scientiﬁc journals.
Additionally relevant to FGR, consideration needs to be given to
methods of monitoring fetal loss and growth. Serial measurement
in one animal may yield more information than multiple post
mortem sampling in a number of different animals. In particular
measurement of uterine blood ﬂow is feasible in large animals
using ultrasound or implanted ﬂow probes and may yield valuable
longitudinal data after intervention [72e74]. Ultrasound allows
non-invasive longitudinal monitoring, although it does require
skilled technicians, who should be blinded to the intervention
where possible [75]. Care should be taken when assessing whether
pups are resorbed or not, especially with regard to whether this is
due to the intervention/therapy or the creation of FGR.
If animals are going to deliver their offspring there are further
considerations. FGR animals often have a higher rate of pregnancy
complications, leading to higher fetal and perinatal loss rate. The
offspring in some models are very fragile at birth and may be
preferentially cannibalised by rodents, or need sustained inter-
vention in order to thrive, some even occasioning an animal
“neonatal intensive care unit”. Measuring interventions of this
nature accurately is challenging. There may be an effect of the
creation of FGR on the ability of mother to feed offspring. Among
other examples, some FGR ewes have very poor lactation initially
and neonatal lambs may need supplemental colostrum [76]. When
complications occur, they should be fully investigated, with a
detailed post-mortem examination, blood analysis, histology and
microbiological analysis where feasible. Evaluation of important
long term outcomes such as cardiovascular disease, hypertension,
insulin sensitivity and even the F1 generation will need sufﬁcient
initial animal numbers to account for these losses. Finally, and by
no means to be considered last, are the statistical analysis to
evaluate the results which must include consideration of con-
founding variables (mother weight, litter number, pup sex, pup
position etc).
6. Conclusion
Developing new therapies for fetal growth restriction ultimately
requires the use of animal models in which to test efﬁcacy and
safety. The choice of which animal to use will need to take into
consideration the characteristics of pregnancy in the particular
animal, and whether to use naturally occurring FGR or FGR created
by maternal or fetal intervention, or genetic manipulation. It is
important to clearly frame the question being asked, as this will
have consequences for the factor inﬂuencing fetal nutrient delivery
in the model, and also for the applicability of the results to the
human condition. Use of guidelines, such as ARRIVE, will improve
the quality of the study and minimise unnecessary follow-up
studies.
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